Company: CPMV
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001683168-25-006318
Chunk: 25

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-08-19
Form: 10-Q
Item: Part I, Item 1
Chunk 25
---
 covenants and specific financial ratios that may restrict our ability to operate
our business. Since the closing date of the Reverse Merger, our limited cash position has required us to perform only limited development
activities and to delay and scale back our development programs and other activities to remain afloat. If we continue to have insufficient
funds, we may be required to cease our operations altogether.

In addition, the continuation of disruptions caused
by COVID-19 or other related variants, broad-based inflation, and various economic indicators that the United States economy may be entering
a recession in upcoming quarters may cause investors to slow down or delay their decision to deploy capital which will adversely impact
our ability to fund future operations. Consequently, there can be no assurance that any additional financing on commercially reasonable
terms, or at all, will be available when needed. If we are unable to raise additional capital and continue to have insufficient funds,
we may be required to cease our operations altogether. The above matters raise substantial doubt regarding our ability to continue as
a going concern.

Cash Flow Summary 

The following table provides a summary of our net cash flow activity for
the six months ended June 30, 2025 and 2024:

    Six Months Ended June 30, 2025  
    Six Months Ended June 30, 2024 
  
    Net cash used in operating activities 
    $(61,436) 
    $(207,444)
  
    Net cash provided by financing activities 
     –  
     55,000 
  
    Net change in cash and cash equivalents 
    $(61,436) 
    $(152,444)

Cash Flows From Operating Activities 

Net cash used in operating activities for the six
months ended June 30, 2025 consisted of our net loss of $353,348, which amount was offset by (i) non-cash interest expense of $36,365
and (ii) a net change in operating assets and liabilities of $255,247, primarily due to an increase in accrued compensation of $244,346.

Net cash used in operating activities for the six
months ended June 30, 2024 consisted of our net loss of $582,209, which amount was offset by (i) non-cash share-based compensation expense
of $4,867, (ii) non-cash interest expense of $37,698, (iii) the accretion to redemption value on convertible notes of $1,446, and (